Effect of mutations at active site residues on the activity of ornithine decarboxylase and its inhibition by active site-directed irreversible inhibitors.
about
Putrescine biosynthesis in mammalian tissuesTranslocation of ornithine decarboxylase to the surface membrane during cell activation and transformationRole of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferationIdentification of essential active-site residues in ornithine decarboxylase of Nicotiana glutinosa decarboxylating both L-ornithine and L-lysineElevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation.Functional roles of the dimer-interface residues in human ornithine decarboxylase.Determinants of the differential antizyme-binding affinity of ornithine decarboxylaseGlutamate, Ornithine, Arginine, Proline, and Polyamine Metabolic Interactions: The Pathway Is Regulated at the Post-Transcriptional LevelMolecular cloning and characterization of ornithine decarboxylase cDNA of the nematode Panagrellus redivivusCritical factors determining dimerization of human antizyme inhibitor.Experimental evidence for structure-activity features in common between mammalian histidine decarboxylase and ornithine decarboxylase.Dimerization of Bacterial Diaminopimelate Decarboxylase Is Essential for Catalysis.Molecular cloning and functional identification of a plant ornithine decarboxylase cDNA.Mutation of cysteine 111 in Dopa decarboxylase leads to active site perturbation.Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.Immediate response of mammalian target of rapamycin (mTOR)-mediated signalling following acute resistance exercise in rat skeletal muscle.Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex.
P2860
Q24530781-21F04686-E0E7-4231-8BF5-CC1BF97952F2Q24533660-6D57370E-9AEB-4D45-AF5F-90A158FA91E3Q28205767-2BCEEE52-C020-41C1-A610-3BC7F2613917Q28365867-1A52BAF6-921F-4B50-BC66-BD0C6E09F035Q33930612-C07134C9-1FCF-4D21-A3A4-03366F4DB75BQ34070766-5E2F5D92-D9C4-4989-B15C-808228FD0FFDQ34071636-833FB72A-0CA6-493E-9CF8-810ED3835567Q36582565-002BDE30-1A01-444F-894C-A7A5BC2F93B8Q36706548-5E76EA4B-299C-4CD7-9E73-EDAA85508AAAQ37446803-08BB23C6-FC98-4B67-B598-8BFFE4B33DCEQ38351059-FFA1E01B-49D2-4A37-9861-6A785085BC68Q40789623-7F3ACF36-32ED-4033-A14E-C93ED0260B28Q42203196-1CEE711F-09BA-4D33-B31C-5BE14698A6B1Q42846047-376F2333-A470-413A-8BF0-BE83C885D48AQ43003172-5BB84C50-D427-48D3-85DF-F0E9E615C5A2Q44560775-9575626D-E9DC-4A77-94F0-7C354493C22DQ52326182-32D494E9-50C5-4E5B-B125-1039E933F85C
P2860
Effect of mutations at active site residues on the activity of ornithine decarboxylase and its inhibition by active site-directed irreversible inhibitors.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Effect of mutations at active ...... ected irreversible inhibitors.
@ast
Effect of mutations at active ...... ected irreversible inhibitors.
@en
type
label
Effect of mutations at active ...... ected irreversible inhibitors.
@ast
Effect of mutations at active ...... ected irreversible inhibitors.
@en
prefLabel
Effect of mutations at active ...... ected irreversible inhibitors.
@ast
Effect of mutations at active ...... ected irreversible inhibitors.
@en
P1476
Effect of mutations at active ...... rected irreversible inhibitors
@en
P2093
P304
24572-24579
P407
P577
1993-11-01T00:00:00Z